VCYT News and Press, Veracyte Inc. From 01/23/23

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk,...

It's no secret that growth stocks struggled mightily in 2022 amid high inflation and surging interest rates. This is at least partially why the Nasdaq Composite shed a third of its value last year. And many growth stocks were hit even harder. Share prices of genetic testing company Vera...

Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...

Meta-analysis of 13 independent studies suggests genomic test performs even better in real-world clinical practice as compared to original clinical validation study Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the...

Summary CareDx reported lackluster performance in the third quarter, with core testing revenue down by 2.5%, mirroring intensifying competitive dynamics impacting its pricing power. Competitive dynamics are exacerbated by the company's expansion in niche markets with structurally ...

Summary GH's aberrant trading pattern after its Q3 earnings release on Friday mirrors two conflicting trends arising from the company's unique market position. A new paradigm in the gene testing market is now emphasizing clearer paths to profitability, contradicting GH's spending ...

Summary VCYT exceeded investors' expectations, coupling solid revenue growth with improved profitability. Unique international exposure offers revenue tailwinds as Europe accelerates gene diagnostic testing adoption. In view of the probability that the political and regulatory...

Veracyte ( NASDAQ: VCYT ) is trading 10.6% higher premarket after the company raised its full-year 2022 forecast and posted 25% Y/Y rise in quarterly revenue, helped by strong performance in Decipher and Afirma tests. The company is raising full-year 2022 total...

Veracyte, Inc. (VCYT) Q3 2022 Earnings Conference Call November 2, 2022 4:30 AM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Executive Vice President and Chief Financial Officer ...